Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

Cancer ◽  
2003 ◽  
Vol 97 (11) ◽  
pp. 2760-2766 ◽  
Author(s):  
Jorge Cortes ◽  
Francis Giles ◽  
Susan O'Brien ◽  
Deborah Thomas ◽  
Maher Albitar ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
High Risk ◽  
Myelodysplastic Syndrome ◽  
Imatinib Mesylate ◽  
Myeloid Leukemia ◽  
Myeloproliferative Disorders ◽  
Acute Myeloid

A Real Life Turkish Experience Of Venetoclax Treatment In High Risk Myelodysplastic Syndrome And Acute Myeloid Leukemia

2021 ◽  
Author(s):  
Aliihsan Gemici ◽  
Fahir Ozkalemkas ◽  
Mehmet Hilmi Dogu ◽  
Atakan Tekinalp ◽  
Inci Alacacioglu ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
High Risk ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Real Life ◽  
Acute Myeloid

Outcome of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome According to Health Insurance Status

2014 ◽  
Vol 14 (6) ◽  
pp. 509-513 ◽  
Author(s):  
Ali Al-Ameri ◽  
Ankit Anand ◽  
Mohamed Abdelfatah ◽  
Zeyad Kanaan ◽  
Tracy Hammonds ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Health Insurance ◽  
High Risk ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Insurance Status ◽  
Health Insurance Status ◽  
Acute Myeloid

scholarly journals Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Leukemia ◽  
2018 ◽  
Vol 33 (2) ◽  
pp. 379-389 ◽  
Author(s):  
Jorge E. Cortes ◽  
Florian H. Heidel ◽  
Andrzej Hellmann ◽  
Walter Fiedler ◽  
B. Douglas Smith ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
High Risk ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Low Dose ◽  
Newly Diagnosed ◽  
Low Dose Cytarabine ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document